Korsana Biosciences at Stifel 2026 Healthcare Conference 2026: cash-rich push
On Tuesday, 10 November 2026, Korsana Biosciences (KRSA) utilized the Stifel 2026 Healthcare Conference to present a strategy centered around Alzheimer's disease. The biopharmaceutical company unveiled its lead program, KRSA-028, which aims to enhance the efficacy of current amyloid therapies by focusing on improved brain delivery and reduced tolerability issues.
As of the end of September, KRSA had a cash reserve of $456 million, providing enough funds for operations until 2029. The drug candidate, KRSA-028, targets pyroglutamate-modified amyloid-beta with the use of transferrin receptor shuttle technology, with an objective to maintain the plaque-clearing benefits of amyloid antibodies while mitigating safety concerns.
KRSA is planning to present healthy-volunteer data in mid-2025 and interim proof-of-concept data in early Alzheimer's disease patients by late 2025 or the first quarter of 2028. Despite the crowded field and the challenge of proving the approach's clinical translation, Korsana's management expressed confidence in their company's position in the Alzheimer's treatment market, which remains large and underpenetrated.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
